Psoriasis - recent advances in understanding its pathogenesis and treatment

被引:168
作者
Krueger, G
Ellis, CN
机构
[1] Univ Utah, Hlth Sci Ctr, Dept Dermatol, Salt Lake City, UT 84132 USA
[2] Univ Michigan, Sch Med, Dept Dermatol, Ann Arbor, MI 48109 USA
关键词
D O I
10.1016/j.jaad.2005.04.035
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Although not completely understood, there is clearly a genetic component in the development of psoriasis. Twin Studies show a 67% concordance for monozygotic twins versus 18% for dizygotic twins. This lack of complete concordance in monozygotic twins Suggests multifactorial inheritance and interaction between genetic predisposition and the environment. At present, 8 different psoriasis susceptibility loci have been identified in genome-wide linkage scans, including locations on 15 different chromosomes. Genetic connections have been made between psoriasis and other diseases, including atopic dermatitis, rheumatoid arthritis, and Crohn's disease. A variety of approaches are available for the treatment of psoriasis, ranging from topical agents for milder forms of the disease to phototherapy and systemic agents for severe psoriasis. Despite the importance of systemic therapies and recent advances represented by biologic agents, topical treatments will probably remain the mainstay of psoriasis therapy for most patients. The advent of new, cosmetically attractive vehicles may enhance corripliance, add to the use of topical agents, and potentially improve patient outcomes.
引用
收藏
页码:S94 / S100
页数:7
相关论文
共 49 条
[21]   CYCLOSPORINE FOR PLAQUE-TYPE PSORIASIS - RESULTS OF A MULTIDOSE, DOUBLE-BLIND TRIAL [J].
ELLIS, CN ;
FRADIN, MS ;
MESSANA, JM ;
BROWN, MD ;
SIEGEL, MT ;
HARTLEY, AH ;
ROCHER, LL ;
WHEELER, S ;
HAMILTON, TA ;
PARISH, TG ;
ELLISMADU, M ;
DUELL, E ;
ANNESLEY, TM ;
COOPER, KD ;
VOORHEES, JJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (05) :277-284
[22]   CYCLOSPORINE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC USE IN IMMUNOREGULATORY DISORDERS [J].
FAULDS, D ;
GOA, KL ;
BENFIELD, P .
DRUGS, 1993, 45 (06) :953-1040
[23]   PSORIASIS AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION [J].
GARDEMBASPAIN, M ;
IFRAH, N ;
FOUSSARD, C ;
BOASSON, M ;
SAINTANDRE, JP ;
VERRET, JL .
ARCHIVES OF DERMATOLOGY, 1990, 126 (11) :1523-1523
[24]   Etanercept: An overview [J].
Goffe, B ;
Cather, JC .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 49 (02) :S105-S111
[25]   Infliximab for psoriasis [J].
Gottlieb, AB .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 49 (02) :S112-S117
[26]  
Guenther Lyn C, 2002, J Cutan Med Surg, V6, P2
[27]   GLUCOCORTICOID EFFECTS ON THE PRODUCTION AND ACTIONS OF IMMUNE CYTOKINES [J].
GUYRE, PM ;
GIRARD, MT ;
MORGANELLI, PM ;
MANGANIELLO, PD .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1988, 30 (1-6) :89-93
[28]   A genomewide screen in multiplex rheumatoid arthritis families suggests genetic overlap with other autoimmune diseases [J].
Jawaheer, D ;
Seldin, MF ;
Amos, CI ;
Chen, WV ;
Shigeta, R ;
Monteiro, J ;
Kern, M ;
Criswell, LA ;
Albani, S ;
Nelson, JL ;
Clegg, DO ;
Pope, R ;
Schroeder, HW ;
Bridges, SL ;
Pisetsky, DS ;
Ward, R ;
Kastner, DL ;
Wilder, RL ;
Pincus, T ;
Callahan, LF ;
Flemming, D ;
Wener, MH ;
Gregersen, PK .
AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 68 (04) :927-936
[29]   PSORIASIS AND BONE-MARROW TRANSPLANTATION [J].
JOWITT, SN ;
YIN, JAL .
BRITISH MEDICAL JOURNAL, 1990, 300 (6736) :1398-1399
[30]   Two considerations for patients with psoriasis and their clinicians: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? [J].
Krueger, GG ;
Feldman, SR ;
Camisa, C ;
Duvic, M ;
Elder, JT ;
Gottlieb, AB ;
Koo, J ;
Krueger, JG ;
Lebwohl, M ;
Lowe, N ;
Menter, A ;
Morison, WL ;
Prystowsky, JH ;
Shupack, JL ;
Taylor, JR ;
Weinstein, GD ;
Barton, TL ;
Rolstad, T ;
Day, RM .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 43 (02) :281-285